Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase. 1991

P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
Queensland Institute of Medical Research, Brisbane, Australia.

Systemically administered 4-S-cysteaminylphenol (4-S-CAP) and N-acetyl-4-S-CAP inhibited the growth of xenografts of a human melanoma cell line but not of an ovarian tumour cell line. No selective cytotoxicity for melanoma cells was observed in culture, however. Further study of the in vitro mechanism of 4-S-CAP toxicity showed minimal inhibition of tyrosinase activity or DNA, RNA and protein synthesis, and there was no phase-specific arrest of the cell cycle. However, expression of an 80 kD melanosomal antigen was decreased. Cytotoxicity of 4-S-CAP in culture was decreased by simultaneous treatment with a monoamine oxidase inhibitor. An affinity column prepared from 4-S-CAP retained several proteins from a melanoma cell lysate. One protein, found also in HeLa cells, was identified by N-terminal sequencing as protein disulphide isomerase, a molecule which has multiple roles in the modification of secretory proteins. These results identify a protein target for 4-S-CAP as one possible mechanism of cytotoxicity.

UI MeSH Term Description Entries
D007535 Isomerases A class of enzymes that catalyze geometric or structural changes within a molecule to form a single product. The reactions do not involve a net change in the concentrations of compounds other than the substrate and the product.(from Dorland, 28th ed) EC 5. Isomerase
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine

Related Publications

P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
March 1992, Cancer letters,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
July 1989, Biochemical pharmacology,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
January 1992, Cancer chemotherapy and pharmacology,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
March 1990, Biochemical pharmacology,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
January 2017, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
April 2004, Melanoma research,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
January 1993, Journal of cancer research and clinical oncology,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
December 2003, Melanoma research,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
May 2006, Nature,
P G Parsons, and D Favier, and M McEwan, and H Takahashi, and K Jimbow, and S Ito
April 2005, Biochemical and biophysical research communications,
Copied contents to your clipboard!